UNCY vs. CARA, NXTC, LEXX, SNSE, NBRV, EYEN, BOLT, IMRX, VYNE, and XLO
Should you be buying Unicycive Therapeutics stock or one of its competitors? The main competitors of Unicycive Therapeutics include Cara Therapeutics (CARA), NextCure (NXTC), Lexaria Bioscience (LEXX), Sensei Biotherapeutics (SNSE), Nabriva Therapeutics (NBRV), Eyenovia (EYEN), Bolt Biotherapeutics (BOLT), Immuneering (IMRX), VYNE Therapeutics (VYNE), and Xilio Therapeutics (XLO). These companies are all part of the "pharmaceutical preparations" industry.
Unicycive Therapeutics (NASDAQ:UNCY) and Cara Therapeutics (NASDAQ:CARA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, community ranking, dividends and risk.
In the previous week, Cara Therapeutics had 3 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 12 mentions for Cara Therapeutics and 9 mentions for Unicycive Therapeutics. Cara Therapeutics' average media sentiment score of -0.04 beat Unicycive Therapeutics' score of -0.17 indicating that Cara Therapeutics is being referred to more favorably in the news media.
Cara Therapeutics received 647 more outperform votes than Unicycive Therapeutics when rated by MarketBeat users. Likewise, 75.00% of users gave Cara Therapeutics an outperform vote while only 65.52% of users gave Unicycive Therapeutics an outperform vote.
40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 44.7% of Cara Therapeutics shares are owned by institutional investors. 42.0% of Unicycive Therapeutics shares are owned by company insiders. Comparatively, 3.1% of Cara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Unicycive Therapeutics currently has a consensus price target of $5.30, suggesting a potential upside of 390.74%. Cara Therapeutics has a consensus price target of $11.12, suggesting a potential upside of 1,363.35%. Given Cara Therapeutics' higher probable upside, analysts clearly believe Cara Therapeutics is more favorable than Unicycive Therapeutics.
Unicycive Therapeutics has a beta of 2.72, meaning that its share price is 172% more volatile than the S&P 500. Comparatively, Cara Therapeutics has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500.
Unicycive Therapeutics has a net margin of 0.00% compared to Cara Therapeutics' net margin of -723.49%. Unicycive Therapeutics' return on equity of 0.00% beat Cara Therapeutics' return on equity.
Unicycive Therapeutics has higher earnings, but lower revenue than Cara Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Cara Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Unicycive Therapeutics and Cara Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get Unicycive Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding UNCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Unicycive Therapeutics Competitors List
Related Companies and Tools
